Department
Year of Publication
upload
Publication Type
Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone widely recognized for its role in enhancing insulin secretion and improving glycemic control. Beyond its antidiabetic effects, emerging evidence suggests that GLP-1 may influence renal physiology, hematological and glucose levels. This study investigates the subacute toxicity effects of MaxGLP-1 a novel analogue of GLP-1 administration on the kidney, hematological and blood glucose levels in experimental models over a 28 day period. A total of 20 rats were divided into four groups and were fed and given water daily. Group 1 was the control and was exposed to standard feeding and water only, Group 2 was administered 10mg/kg of MaxGLP-1, Group 3 was administered 60mg/kg MaxGLP-1 drug while Group 3 was administered 600mg/kg doses of MaxGLP-1. At the end of the study, animals were sacrificed, the kidneys were harvested and taken to the laboratory to be examined, blood samples were also collected and centrifuged to obtain the serum and were subjected to biochemical assays. Findings showed dose-related changes in serum creatinine and urea, indicating possible renal stress. Haematological analysis revealed mild but notable shifts in erythrocyte and leukocyte indices, while glucose levels decreased significantly across treatment groups. Overall, Max GLP- 1 exhibited hypoglycaemic effects with minimal haematological disturbances, though higher doses suggested early signs of renal compromise. These results highlight the need for cautious dose optimization and further investigation into long-term safety
Supervisor(s)
co-supervisor